glp-1 drugs semaglutide How medications are transforming diabetes and weight loss treatment GLP-1 Drugs from the Gray

Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, accelerates cardiometabolic decline and increases mortality risk

Research on the experimental drug petrelintide suggests it is much less likely to cause nausea and vomiting than GLP-1 drugs, but the pace of weight loss is more moderate.

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

The companies are working together to make it easier for companies to offer health plans that include these medications.

In 2025 we saw label expansions for semaglutide and tirzepatide, underscoring a trend toward whole-body health

We report an unusual case of diabetic ketoalkalosis, a mixed acid-base disorder, in a 57-year-old female patient with insulin-dependent T2DM following a switch to Mounjaro (tirzepatide)